Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

symptoms

- PMLiVE

Abraxane on course for lung cancer indication in EU

CHMP backs news indication for Celgene drug

- PMLiVE

Novartis’ Cosentyx cleared for psoriasis in Europe

First of the IL-17 inhibitor classof drug to receive European approval

- PMLiVE

UCB moves Cimzia into phase III trials for psoriasis

Firm collaborating with Dermira to test efficacy and safety of drug

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

- PMLiVE

Celgene promotes senior EMEA figures

Marie-France Tschudin and Stefano Portolano take on new roles

- PMLiVE

Novartis’ Cosentyx beats Stelara in psoriasis study

Cosentyx achieved clearance in 70% of patients

- PMLiVE

Building a business that is lean and specialised

Tuomo Pätsi on Celgene’s approach to access, marketing and the importance of culture

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

UK flag

UK knows ‘almost nothing’ about pancreatic cancer

Celgene-sponsored survey shows 64% of people know little about the disease

- PMLiVE

Celgene wins orphan drug award at PMEA

Company is recognised for providing early access to Imnovid in multiple myeloma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links